The Clinical Edge

The Clinical Edge

This Could Be Our First Multibagger...

Up 66% in six weeks. The Q1 print confirms the thesis. And it is not the only idea in the portfolio inflecting at once.

The Clinical Edge's avatar
The Clinical Edge
May 19, 2026
∙ Paid

To read our full disclaimer, click here.

Six weeks ago I published a deep dive on a name almost nobody was talking about.

One Drug. One Unsolved Problem. A 10x Market Expansion.

One Drug. One Unsolved Problem. A 10x Market Expansion.

The Clinical Edge
·
Mar 31
Read full story

Today the stock is up roughly 66%, the company has just reported its first GAAP-profitable quarter (a milestone that was not on management’s calendar for 2026), and every leg of the original thesis is starting to show up in the numbers.

What I find more exciting than the move itself is that this is not the only name doing this right now.

Across the archive, several of the names we have covered over the past year are inflecting at the same time. Earnings prints are confirming theses. Operating leverage is starting to land. Optionality stacks are widening.

We may be on the verge of our first multi-bagger, and possibly more than one.

Upgrade Subscription

For paid subscribers below:

  • The full Q1 update on this idea.

  • The new numbers worth watching.

  • What changed in the option stack.

  • How the valuation looks after the move.

  • And my updated view on the stock from here.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2026 The Clinical Edge · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture